AbbVie Signs Partnership with Japanese Drugmaker for Drugs Targeting Inflammatory Diseases

AbbVie has partnered with Japanese drugmaker Sosei Heptares to develop small molecules targeting inflammatory and autoimmune diseases.

Sosei will fund research and development of investigational new drugs, and AbbVie will have an option to license the therapies for global development and commercialization.

Sosei is eligible to receive $32 million in upfront and near-term milestone payments, and up to $377 million in future payments.